The incidence of papillary thyroid cancer is increasing by about 6% per year.
Papillary thyroid cancer is not usually life threatening, but recurrence after treatment can significantly affect quality of life. Identifying high risk individuals helps to direct appropriately aggressive treatment to those who need it. At the same time, confidently identifying individuals with a very low risk of recurrence will help select when more conservative treatment can be offered.
Thyroid GuidePx® is performed on next generation sequencing (RNASeq). The test provides a molecular sub-classification of papillary thyroid cancer that is based on the expression of 82 genes.
Thyroid GuidePx® simplifies prognostication, and identifies a low risk group with <5% recurrence rate.
For questions about Thyroid GuidePx or ordering details, contact us at:
Phone: 1 (754) 242 9682 | Email: support@proteanbiodx.com
